Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123159 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN HBV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 60
- Enrollment target
NCT03123159: Clinical Trial study, sponsored by Beckman Coulter.
NCT03123159 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03123159 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The DxN Hepatitis B Virus (HBV) Assay is an in vitro diagnostic assay intended as an aid in the management of HBV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HBV Assay for plasma samples in the intended use population.
Primary Outcome
Defined as unquantifiable HBV Viral load at 48 weeks of treatment.
Interventions
- DIAGNOSTIC_TEST DxN HBV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2017-08-30 |
Why NCT03123159 stopped before completion
NCT03123159 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DxN HBV Assay is the first listed.
NCT03123159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03123159 about?
NCT03123159 is a clinical study titled "Clinical Performance Evaluation of DxN HBV Assay". The DxN Hepatitis B Virus (HBV) Assay is an in vitro diagnostic assay intended as an aid in the management of HBV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HBV Assay for plasma samples in the intended use populatio...
What is the current status of trial NCT03123159?
This trial is currently terminated. The enrollment target is 60 participants. The study started on 2014-05-27. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03123159?
The interventions under investigation include: DxN HBV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03123159?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI